508 related articles for article (PubMed ID: 36738380)
21. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
[TBL] [Abstract][Full Text] [Related]
23. Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection.
Franchi M; Pellegrini G; Cereda D; Bortolan F; Leoni O; Pavesi G; Galli M; Valenti G; Corrao G
J Infect Public Health; 2023 Aug; 16(8):1137-1141. PubMed ID: 37267680
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
25. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
26. The way of SARS-CoV-2 vaccine development: success and challenges.
Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
[TBL] [Abstract][Full Text] [Related]
27. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines.
Spinardi JR; Srivastava A
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830907
[TBL] [Abstract][Full Text] [Related]
28. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review.
Fiolet T; Kherabi Y; MacDonald CJ; Ghosn J; Peiffer-Smadja N
Clin Microbiol Infect; 2022 Feb; 28(2):202-221. PubMed ID: 34715347
[TBL] [Abstract][Full Text] [Related]
29. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.
Kyei-Barffour I; Addo SA; Aninagyei E; Ghartey-Kwansah G; Acheampong DO
Biomed Pharmacother; 2021 Dec; 144():112282. PubMed ID: 34624675
[TBL] [Abstract][Full Text] [Related]
30. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
31. Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination.
Sasanami M; Fujimoto M; Kayano T; Hayashi K; Nishiura H
J Theor Biol; 2023 Feb; 559():111384. PubMed ID: 36528092
[TBL] [Abstract][Full Text] [Related]
32. Cross-protective immunity following coronavirus vaccination and coronavirus infection.
Dangi T; Palacio N; Sanchez S; Park M; Class J; Visvabharathy L; Ciucci T; Koralnik IJ; Richner JM; Penaloza-MacMaster P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34623973
[TBL] [Abstract][Full Text] [Related]
33. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
Hogan AB; Winskill P; Watson OJ; Walker PGT; Whittaker C; Baguelin M; Brazeau NF; Charles GD; Gaythorpe KAM; Hamlet A; Knock E; Laydon DJ; Lees JA; Løchen A; Verity R; Whittles LK; Muhib F; Hauck K; Ferguson NM; Ghani AC
Vaccine; 2021 May; 39(22):2995-3006. PubMed ID: 33933313
[TBL] [Abstract][Full Text] [Related]
34. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
[TBL] [Abstract][Full Text] [Related]
35. Vaccination against COVID-19 and society's return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine-induced immunity.
Song F; Bachmann MO
BMJ Open; 2021 Nov; 11(11):e053507. PubMed ID: 34785556
[TBL] [Abstract][Full Text] [Related]
36. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.
Pecetta S; Kratochvil S; Kato Y; Vadivelu K; Rappuoli R
Pharmacol Rev; 2022 Jan; 74(1):313-339. PubMed ID: 35101964
[TBL] [Abstract][Full Text] [Related]
37. Acquired immunity against SARS-CoV-2 infection and vaccination.
Renia L; Ng LF
EMBO Mol Med; 2023 Dec; 15(12):e16345. PubMed ID: 37966373
[TBL] [Abstract][Full Text] [Related]
38. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar.
Tayar E; Abdeen S; Abed Alah M; Chemaitelly H; Bougmiza I; Ayoub HH; Kaleeckal AH; Latif AN; Shaik RM; Al-Romaihi HE; Al-Thani MH; Bertollini R; Abu-Raddad LJ; Al-Khal A
J Infect Public Health; 2023 Feb; 16(2):250-256. PubMed ID: 36603377
[TBL] [Abstract][Full Text] [Related]
40. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
Jentsch PC; Anand M; Bauch CT
Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
